Get the app
USHealthcare

Adapthealth Corp (AHCO)

US · Healthcare · Medical Devices

$5.76-2.54%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$740.3M
Revenue YoY
+25.1%
Net profit
$-133.9M
Profit YoY
-1012.7%
EPS
$0.03
EPS estimate
$-0.01
Net margin
-18.1%

EPS came in at 0.03 against a street estimate of -0.01 — a beat of 400.0%.

Key statistics

Market cap
$776.4M
Forward P/E
7.8
P/B
0.57
Book value
$10.34
EPS (TTM)
$-1.70
52-week high
$13.43
52-week low
$5.21
50-day MA
$7.86
200-day MA
$9.90
Beta
1.39

Analyst view

Analysts rate Adapthealth Corp a buy (6 buy, 2 hold, 0 sell out of 8) with an average price target of $9.14.

Shareholding

Insiders
8.18%
Institutions
108.49%

Largest institutional holders

FundStake
OEP CAPITAL ADVISORS, L.P.12.23%
BlackRock Inc11.95%
Deerfield Management Co8.60%
SkyKnight Capital, L.P.6.43%
FMR Inc6.04%
Dimensional Fund Advisors, Inc.5.75%
Reinhart Mahoney Capital Management Inc5.56%
Vanguard Portfolio Management, LLC4.58%

Recent filings & reports

DocumentDate
Board / officer change · Q3 2026
ADAPTHEALTH CORP. - FORM 8-K SUMMARY HEADLINE NUMBERS • New CFO base salary: $670,000 annually • New CFO target bonus: 100% of base salary ($670,000
2026-09-08
Quarterly report · Q2 2026
ADAPTHEALTH CORP. – FORM 10-Q SUMMARY For Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Net Revenue (Q2 2026): $740.3 million | YoY: +12.7% vs
2026-08-04
Results announced · Q3 2026
ADAPTHEALTH CORP. – Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Net revenue Q2 2026: $740.3 million vs. $657.1 million Q2 2025 (+12.7%) • Organic re
2026-08-04
Material agreement · Q3 2026
ADAPTHELTH CORP. – FORM 8-K SUMMARY HEADLINE NUMBERS • Asset sale price: $235.0 million in cash for substantially all diabetes medical devices and s
2026-07-20
Reg FD disclosure · Q3 2026
ADAPTHEALTH CORP. – FORM 8-K SUMMARY HEADLINE NUMBERS • Debt Redemption Amount: $325,000,000 in 6.125% Senior Notes due 2028 being redeemed at 100%
2026-07-07
Quarterly report · Q1 2026
ADAPTHEALTH CORP. (AHCO) – Q1 2026 SUMMARY HEADLINE NUMBERS • Revenue Q1 2026: $819.8 million (up from $777.9 million in Q1 2025; +5.4% YoY) • Net L
2026-05-05
Proxy statement · Q2 2026
ADAPTHEALTH CORP. PROXY SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect nine directors for one-year terms: Gregory Belinfanti, Terence C
2026-04-28
Annual report FY2025
ADAPTHEALTH CORP. - 2025 ANNUAL REPORT SUMMARY HEADLINE NUMBERS • Market capitalization (as of June 30, 2025): approximately $1.04 billion • Outstan
2026-02-24

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Adapthealth Corp — free to start.

Google PlayApp Store

Other Healthcare companies

Data updated 2026-09-18.